Biogen Inc. (NASDAQ: BIIB) announced it will present late-breaking data from its AMETHYST Phase 2 study of litifilimab for cutaneous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE